These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20216419)

  • 41. [Optical coherence tomography in geographic atrophy--a clinicopathologic correlation].
    Hassenstein A; Rühl R; Richard G
    Klin Monbl Augenheilkd; 2001 Jul; 218(7):503-9. PubMed ID: 11512251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration.
    Sunness JS; Applegate CA; Gonzalez-Baron J
    Retina; 2000; 20(2):162-9. PubMed ID: 10783949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Treatment Modalities for Geographic Atrophy.
    Kandasamy R; Wickremasinghe S; Guymer R
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):508-513. PubMed ID: 28905539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
    Vakharia P; Eichenbaum D
    Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR; Del Priore LV
    Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid recurrence of geographic atrophy after full macular translocation for nonexudative age-related macular degeneration.
    Khurana RN; Fujii GY; Walsh AC; Humayun MS; de Juan E; Sadda SR
    Ophthalmology; 2005 Sep; 112(9):1586-91. PubMed ID: 16051364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial.
    Complications of Age-Related Macular Degeneration Prevention Trial Research Group
    Ophthalmology; 2006 Nov; 113(11):1974-86. PubMed ID: 17074563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
    Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G
    J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
    Grisanti S; Tatar O
    Prog Retin Eye Res; 2008 Jul; 27(4):372-90. PubMed ID: 18621565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):15-16. PubMed ID: 38212259
    [No Abstract]   [Full Text] [Related]  

  • 51. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576-586).
    Pfau M
    Ophthalmology; 2021 Dec; 128(12):e219. PubMed ID: 34600774
    [No Abstract]   [Full Text] [Related]  

  • 52. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586).
    Keenan TDL
    Ophthalmology; 2021 May; 128(5):e25-e26. PubMed ID: 33551286
    [No Abstract]   [Full Text] [Related]  

  • 53. Beta blocker use and age-related macular degeneration.
    Davis A; Cohen SM; Pautler SE; Billiris-Findlay K; Eichenbaum DA
    Acta Ophthalmol; 2012 Mar; 90(2):e162-3. PubMed ID: 21649869
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic targeting of the complement system in ocular disease.
    Rathi S; Hasan R; Ueffing M; Clark SJ
    Drug Discov Today; 2023 Nov; 28(11):103757. PubMed ID: 37657753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review.
    Schmitz-Valckenberg S; Sadda S; Staurenghi G; Chew EY; Fleckenstein M; Holz FG;
    Retina; 2016 Dec; 36(12):2250-2264. PubMed ID: 27552292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The complement system: a novel therapeutic target for age-related macular degeneration.
    Shughoury A; Sevgi DD; Ciulla TA
    Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26.
    Feuer WJ; Yehoshua Z; Gregori G; Penha FM; Chew EY; Ferris FL; Clemons TE; Lindblad AS; Rosenfeld PJ
    JAMA Ophthalmol; 2013 Jan; 131(1):110-1. PubMed ID: 23307222
    [No Abstract]   [Full Text] [Related]  

  • 58. Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.
    Cioffi CL; Racz B; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DM; Zhu L; Kitchen DB; Barnes KD; Dobri N; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K
    J Med Chem; 2015 Aug; 58(15):5863-88. PubMed ID: 26181715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of geographic atrophy: an update on data related to pegcetacoplan.
    Patel SB; Heier JS; Chaudhary V; Wykoff CC
    Curr Opin Ophthalmol; 2024 Jan; 35(1):64-72. PubMed ID: 37815317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration.
    Dugel PU; Novack RL; Csaky KG; Richmond PP; Birch DG; Kubota R
    Retina; 2015 Jun; 35(6):1173-83. PubMed ID: 25932553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.